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Cisplatin (CDDP) is one of the most effective drugs for the treat-
ment of human solid tumours. However, its therapeutic efficacy is
limited by the emergence of tumour cell subpopulations with
intrinsic or treatment-induced resistance. Multinuclear platinum
compounds represent a new approach to circumvent cellular resis-
tance to CDDP in that they are endowed with a different DNA-
binding profile compared to their mononuclear counterparts
(Perego et al, 1999; Manzotti et al, 2000). BBR 3464, which has
been identified as the most active member of this class of
compounds, is more potent than CDDP (Brabec et al, 1999) and is
active in CDDP-resistant experimental human tumour models
(Pratesi et al, 1999). However, the cellular determinants respon-
sible for BBR 3464 activity are largely unknown. 
In the present study we evaluated the cytotoxic activity of BBR
3464 in 2 pairs of human ovarian cancer cell lines sensitive and
with experimentally induced resistance to CDDP. Moreover, in an
attempt to elucidate the relevance of DNA repair on the cellular
response to BBR 3464, we assessed in our cellular models the
expression of mismatch repair (MMR) and nucleotide excision
repair (NER) genes as well as the kinetics of accumulation and
removal of drug-induced lesions at the single-gene (N-ras) level. 
MATERIALS AND METHODS 
Cell lines and growth inhibition assay 
Two human ovarian cancer cell lines, OAW42 and A2780, and their
corresponding CDDP-resistant sublines. OAW42MER (Britten 
et al, 1990) and A2780cp8 (Beherens et al, 1987) were used in the
study. The A2780d cell clone, which was selected in culture without
drug exposure was also used. Cells in the logarithmic growth phase
were exposed to various concentrations of CDDP (Pharmacia-
Upjohn, Milan, Italy) and BBR 3464 (Novuspharma S.p.A., Monza,
Italy) for 1 h. After a 72-h incubation with drug-free medium, cells
were trypsinized and counted in a particle counter (Coulter Counter,
Coulter Electronics, Luton, UK). The results were expressed as the
number of cells in treated samples compared with control samples.
In vitro drug activity was expressed as the concentration able to
inhibit cell growth in treated samples by 50% (IC50). 
Nuclear extracts and western blotting 
Nuclear lysate (Dignam et al, 1983) was separated on 8% or 12%
SDS-PAGE and transferred to nitrocellulose. Filters were probed
with the primary antibodies anti-hMLH1, anti-hMSH2, anti-
hPMS2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
ERCC1 and anti-tubulin b (Neomarkers, Union City, CA, USA),
and then incubated with the secondary anti-mouse or anti-rabbit
IgG horseradish peroxidase-linked whole antibodies (Amersham
Pharmacia Biotech, Uppsala, Sweden). Bound antibody was
detected using the enhanced chemoluminescence Western blotting
detection system (Amersham). 
RNA isolation and Reverse Transcription-PCR 
Total RNA was extracted from frozen cells using Trizol reagent
(Life Technologies Italia, Milan, Italy). Reverse transcription-
PCR was performed by means of the RNA PCR Core Kit 
(Perkin Elmer-Roche, Foster City, CA, USA). Primers used 
were: ERCC1 sense 5¢-GTGCAGTCGGCCAGGATACAC-3¢ and 
antisense 5¢-GTCCTCCTGGAGTGGCCAAG-3¢,  b-actin sense
5¢-GGGAATTCAAAACTGGAACGGTGAAGG-3¢ and antisense
5¢-GGAAGCTTATCAAAGTCCTCGGCCACA-3¢. PCR products
were loaded on a 3% agarose gel and bands were quantified after
staining with ethidium bromide. 
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Cells were incubated for 5 h with CDDP and BBR 3464 and
collected immediately after drug removal or following an addi-
tional 6,24 or 48 h of incubation in drug-free medium. Cell mono-
layers were recovered from the Petri dish using a cell scraper,
pelleted by centrifugation and counted. The cell pellet was resus-
pended in lysis buffer and incubated at 60˚C for 2 h and at 95˚C 
for 15 min. After centrifugation the DNA-containing cell lysate
was diluted and the quantitative PCR assay was performed 
as described (Koberle et al, 1996) by means of N-ras sense 
(5¢-CCTTAATCTGTCCAAAGCAGAGGC-3¢) and antisense 
(5¢-CAGCAAGAACCTGTTGGAAACCAG-3¢) primers, and b-actin
sense and antisense primers. PCR products were separated on a
5% non-denaturing polyacrylamide gel and visualized by auto-
radiography. Quantification of PCR products was performed by
densitometric analysis using ImageQuant software (Microsoft
Corp., Santa Rosa, CA, USA). 
RESULTS AND DISCUSSION 
Results of cytotoxicity experiments indicated a collateral sensi-
tivity of OAW42MER cells to BBR 3464. In fact, whereas the
cells were 10 times less sensitive to CDDP than the parental
OAW42 cells (IC50: 83.0 ±18.6 mM vs 8.3 ±2.8 mM), they were 14
times more sensitive to BBR 3464 (IC50: 0.36 ± 0.14 mM vs
5.20 ± 1.3 mM). As regards the second pair of cell lines. A2780cp8
cells were 14-fold more resistant to CDDP (IC50: 60.0 ± 5.6 mM vs
4.3 ± 0.35 mM) and only 2.5-fold more resistant to BBR 3464 (IC50:
0.20 ± 0.095 mM vs 0.08 ± 0.008 mM) than the parental A2780
cells. 
OAW42MER and A2780cp8 cells lacked the expression of the
MMR proteins hMLH1 and hPMS2 (Figure 1A) and, compared to
the MMR-proficient OAW42 and A2780 parental cell lines,
showed a marked instability of the microsatellite sequences at
several loci (data not shown). Superimposable results were
observed in the A2780d cell clone, which was selected in culture
without drug exposure and showed a 4.7-fold resistance to CDDP
(IC50 : 20.0 ± 3.25 mM) and exactly the same sensitivity to BBR
3464 (IC50 : 0.077 ± 0.03 mM) as the parental A2780 cell line,
which suggests, in agreement with previous findings (Perego et al,
1999), a lack of influence of MMR status on BBR 3464 cytotoxic
activity. As regards the NER system. ERCC1 mRNA and protein
levels of the OAW42MER cell line were 3 times higher than those
of the OAW42 parental cell line, whereas a comparable expression
of the NER gene was found in the A2780, A2780d and A2780cp8
cells (Figure 1B,C). It has been reported that in Chinese hamster
ovarian cells overexpression of ERCC1 may enhance the sensi-
tivity to alkylating agents because a greater number of DNA
lesions are induced than the other enzymes involved in the
pathway can repair (Bramson and Panasci, 1993). This could
partially explain why among our cell lines those with a high level
of ERCC1 (OAW42MER, A2780 and A2780cp8) were more
sensitive to BBR 3464 than the OAW42 cells, which express less
protein. In fact, the trinuclear compound can produce bulky DNA
lesions, thus inducing ERCC1 to make more incisions than the
remaining NER proteins are able to repair. 
Results obtained from atomic absorption spectrometry and 
mass spectroscopy analysis, following incubation of cells with
equimolar concentrations of the 2 drugs, indicated that the intra-
cellular accumulation of platinum as well as the extent of platinum
bound to DNA was always higher after treatment with BBR 3464
than with CDDP. Such a finding is consistent with an increased
affinity of BBR 3464 to DNA owing to the presence of 2 reactive
platinum centres in the molecule and to the high positive charge
(+4) which could contribute to drug interaction with DNA through
electrostatic and hydrogen binding (Brabec et al, 1999). However,
whereas in CDDP-resistant cells the levels of intracellular plat-
inum and DNA platination were consistently lower than those
detected in sensitive cells, no differences in these parameters
among cell lines, able to justify their peculiar sensitivity/resistance
profile to BBR 3464, were observed (data not shown). 
We did not perform any evaluation on the efficiency of detoxifi-
cation systems (in terms of glutathione and metallothionein
expression) in our cell lines and, therefore, we do not know
whether the detoxification process influences the cellular response
to BBR 3464. 
In an attempt to identify possible molecular determinants of
cellular response to BBR 3464, we focused on the kinetics of
gene-specific repair of lesions produced by the trinuclear platinum
complex in genomic DNA as assessed by a quantitative PCR on
the 523 bp sequence of the N-ras gene intron I. A 98 bp b-actin
gene fragment was coamplified to normalize experimental vari-
ability among samples. Results of preliminary experiments
performed using as a template naked genomic DNA exposed in
vitro to BBR 3464 and CDDP, showed that the extent of amplifica-
tion inhibition and, as a consequence, the level of lesions present
in the N-ras gene were dependent on drug concentration for both
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Figure 1 Analysis of DNA mismatch repair (MMR) and nucleotide excision
repair (NER) status in ovarian cancer cell lines. (A) Western blotting analysis
of hPMS2, hMSH2 and hMLH1 protein expression. HeLa, LoVo and HCT-116
cell lines were used as specific controls for MMR protein expression. The
non-specific lower band in the hMLH1 blot represented a control of protein
loading. (B) Western blotting analysis of ERCC1 protein. (C) RT-PCR
analysis of ERCC1 mRNA agents and confirmed the higher efficiency of BBR 3464 than
CDDP in inducing DNA lesions. In fact, the concentration of BBR
3464 required to induce a 50% amplification inhibition was 14
times lower than that of CDDP (0.013 mM vs 0.183 mM). 
The effect of DNA damage present in the N-ras gene of the 4
ovarian cancer cell lines was then evaluated immediately
following a 5-h exposure of intact cells to CDDP or BBR 3464 and
after an additional 6, 24 or 48 h in drug-free medium (Figure 2A).
The experiments were carried out with the IC50 of CDDP in all cell
lines, whereas in the case of BBR 3464, a 10-fold IC50 was used,
since in A2780, A2780cp8 and OAW42MER cells the IC50 values
of the trinuclear platinum compound were too low to produce a
level of DNA lesions quantifiable by the PCR technique. In
OAW42 cells, a strong inhibition of signal amplification was
observed at the end of CDDP exposure. The level of inhibition
remained almost constant until 24 h after treatment, whereas at 48
h the extent of amplification increased to 67% of control, thus indi-
cating a removal of drug induced DNA damage. Similar results
were obtained after exposure of cells to BBR 3464, although in
this case the extent of amplification after 48 h of recovery was
significantly (P < 0.05) lower than that observed for CDDP and
limited to 33% of control (Figure 2B). In CDDP-treated
OAW42MER cells, an almost complete inhibition of signal
amplification was detected 6 h after treatment. DNA damage was
partially repaired at 24 h, and only very few lesions were still
present at 48 h, as indicated by the extent of amplification, which
was approximately 100% of control. Similar kinetics of DNA
lesion accumulation and removal were observed after exposure of
the cells to BBR 3464 (Figure 2B). 
In A2780 cells, the maximum inhibition of signal amplification
was found at the end of CDDP exposure. Progressive removal of
DNA lesions, with a consequent increase in the extent of amplifi-
cation, was observed starting at 6 h after treatment. At 24 h, the
level of amplification reached 60% of control, and no additional
increase was observed at 48 h. After exposure of the cells to BBR
3464, a negligible inhibition of signal amplification was observed
up to 6 h, thus suggesting a slow conversion of monoadducts to
bifunctional adducts. In fact, although theoretically Taq DNA
polymerase is affected by both types of adduct, the PCR stop assay
is expected to reflect mainly bifunctional adducts and in particular
intrastrand cross-links, which represent the majority of drug
adducts for CDDP (Murray et al, 1992; Bubley et al, 1994) and
probably for BBR 3464 as well (Brabec et al, 1999). The highest
level of amplification inhibition was detected at 24 h and it was
almost unmodified at 48 h (Figure 2B). In A2780cp8 cells, the
extent and the kinetics of accumulation and repair of CDDP-
induced DNA lesions were similar to those observed with the same
drug in A2780 cells, even though in A2780cp8 cells the highest
inhibition of signal amplification (which should indicate the pres-
ence of the greatest number of lesions) was detected 6 h from the
end of treatment. A slow kinetics of DNA lesion induction by BBR
3464 was recorded, and the maximum inhibition of signal amplifi-
cation was detected 24 h after treatment. In these cells, which
showed a moderate degree of resistance to BBR 3464, a slightly
but significantly (P < 0.05) greater increase in the level of amplifi-
cation, with respect to that observed in A2780 cells, was appre-
ciable at 48 h, thus suggesting the ability of the cells to partially
remove DNA damage (Figure 2B). 
The results suggest possible differences in the kinetics of induc-
tion and removal of DNA damage between BBR 3464 and CDDP
that may influence the cellular response to the 2 agents. Moreover,
preliminary evidence suggests that the peculiar sensitivity to
CDDP and BBR 3464 observed in our cellular models may also be
attributable to a different ability to activate other pathways of
cellular response to DNA damage, such as triggering of the apop-
totic pathway, as a function of the genetic background of the
tumour model (Orlandi et  al, 2001). 
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Figure 2 (A) A representative example of quantitative PCR analysis on
genomic DNA (N-ras gene) after a 5-h drug exposure of OAW42MER cells 
to the IC50 of CDDP and 10-fold IC50 of BBR 3464 and after an additional 
6,24 or 48 h of incubation in drug-free medium. Controls: Ct/2 = 625 cell
equivalents. Ct = 1250 cell equivalents. (B) Quantification of PCR reactions
for the N-ras gene following a 5-h incubation to IC50 of CDDP (n) and
10 ´ IC50 of BBR 3464 (n n) in OAW42, OAW42MER, A2780 and A2780cp8
cell lines. The ordinate shows the relative amplification expressed as
percentage of control. Values represent the mean (± SD) of 3 independent
experiments Orlandi L, Colella G, Bearzatto A, Abolafio G, Manzotti C, Daidone MG and
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